drugset / Trial / NCT00844909

A Study of the Safety and How the Body Effects a Drug CNTO 136 in Healthy Male Japanese and Caucasian Volunteers

NCT00844909

Phase 1 Completed 62 enrolled Centocor, Inc.
RandomizedSingle-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the safety, tolerability and how the body affects the drug CNTO 136 in healthy Japanese and Caucasian volunteers.

Timeline

Start
2009-01
Primary completion
Completion
2009-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Sirukumab Monoclonal antibody Subcutaneous

Indications

No indication recorded.